Moreover, chronic oral treatment of AKBA 50 mg/kg and 100 mg/kg showed significant increases in Bcl-2 levels in rat brain homogenate (one-way ANOVA: F(5,25) = 1.958, p < 0.001) as compared to EB-induced MS rats. This evidence concerns the gene BCL2 and myeloid sarcoma.